Tevogen Bio (TVGN) Competitors $1.02 -0.03 (-2.86%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN vs. CVAC, DAWN, ABCL, PAHC, GYRE, NUVB, CRON, EOLS, XERS, and LENZShould you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include CureVac (CVAC), Day One Biopharmaceuticals (DAWN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), Gyre Therapeutics (GYRE), Nuvation Bio (NUVB), Cronos Group (CRON), Evolus (EOLS), Xeris Biopharma (XERS), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. Tevogen Bio vs. CureVac Day One Biopharmaceuticals AbCellera Biologics Phibro Animal Health Gyre Therapeutics Nuvation Bio Cronos Group Evolus Xeris Biopharma LENZ Therapeutics CureVac (NASDAQ:CVAC) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation. Which has more volatility and risk, CVAC or TVGN? CureVac has a beta of 2.48, meaning that its stock price is 148% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500. Does the MarketBeat Community believe in CVAC or TVGN? CureVac received 23 more outperform votes than Tevogen Bio when rated by MarketBeat users. However, 100.00% of users gave Tevogen Bio an outperform vote while only 55.32% of users gave CureVac an outperform vote. CompanyUnderperformOutperformCureVacOutperform Votes2655.32% Underperform Votes2144.68% Tevogen BioOutperform Votes3100.00% Underperform VotesNo Votes Is CVAC or TVGN more profitable? CureVac has a net margin of 20.72% compared to Tevogen Bio's net margin of 0.00%. CureVac's return on equity of 21.98% beat Tevogen Bio's return on equity.Company Net Margins Return on Equity Return on Assets CureVac20.72% 21.98% 15.72% Tevogen Bio N/A -396.07%749.97% Do analysts rate CVAC or TVGN? CureVac presently has a consensus price target of $10.00, suggesting a potential upside of 212.50%. Tevogen Bio has a consensus price target of $7.10, suggesting a potential upside of 596.08%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts plainly believe Tevogen Bio is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Tevogen Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer CVAC or TVGN? In the previous week, CureVac had 15 more articles in the media than Tevogen Bio. MarketBeat recorded 21 mentions for CureVac and 6 mentions for Tevogen Bio. CureVac's average media sentiment score of 0.29 beat Tevogen Bio's score of 0.10 indicating that CureVac is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CureVac 5 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, CVAC or TVGN? Tevogen Bio has lower revenue, but higher earnings than CureVac. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$543.28M1.32-$281.58M$0.823.90Tevogen BioN/AN/A-$70KN/AN/A Do insiders & institutionals have more ownership in CVAC or TVGN? 17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 56.6% of Tevogen Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryCureVac beats Tevogen Bio on 8 of the 15 factors compared between the two stocks. Remove Ads Get Tevogen Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVGN vs. The Competition Export to ExcelMetricTevogen BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$183.80M$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E RatioN/A31.0021.7117.82Price / SalesN/A441.16376.6894.61Price / CashN/A168.6838.1534.64Price / Book-0.953.476.464.00Net Income-$70,000.00-$72.06M$3.20B$247.23M7 Day Performance-6.25%3.17%2.76%1.44%1 Month Performance-10.26%-16.97%-8.61%-6.26%1 Year Performance-55.51%-29.07%10.39%0.59% Tevogen Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVGNTevogen Bio3.8193 of 5 stars$1.02-2.9%$7.10+596.1%-55.3%$178.55MN/A0.003Gap DownCVACCureVac3.3511 of 5 stars$3.27+2.5%$10.00+205.8%+21.9%$732.09M$543.28M5.95880Earnings ReportUpcoming EarningsShort Interest ↑DAWNDay One Biopharmaceuticals2.4462 of 5 stars$7.22+1.4%$32.29+347.2%-48.1%$731.78M$131.16M-7.0160ABCLAbCellera Biologics2.1306 of 5 stars$2.44+1.7%$7.00+186.9%-41.9%$727.09M$28.83M-4.00500Analyst ForecastNews CoverageGap DownPAHCPhibro Animal Health3.8175 of 5 stars$17.91+2.3%$21.00+17.3%+27.3%$725.53M$1.11B37.311,860News CoverageGYREGyre Therapeutics0.1318 of 5 stars$7.72+2.7%N/A-49.0%$722.69M$105.76M154.4040Short Interest ↑Gap DownNUVBNuvation Bio2.4651 of 5 stars$2.03+1.8%$8.75+332.1%-29.7%$673.97M$7.87M-0.9360Positive NewsCRONCronos Group1.5686 of 5 stars$1.72-1.7%$3.50+103.5%-29.5%$662.90M$117.62M-13.23450Gap DownEOLSEvolus3.5021 of 5 stars$10.27+7.7%$24.67+140.2%-14.0%$653.04M$266.27M-11.29170Analyst RevisionGap UpHigh Trading VolumeXERSXeris Biopharma4.3131 of 5 stars$4.16flat$6.10+46.6%+136.8%$640.39M$203.07M-9.24290Short Interest ↑News CoveragePositive NewsGap DownLENZLENZ Therapeutics1.7564 of 5 stars$23.24+14.7%$44.17+90.0%+16.9%$640.10MN/A-4.87110Analyst ForecastNews CoverageGap Down Remove Ads Related Companies and Tools Related Companies CureVac Competitors Day One Biopharmaceuticals Competitors AbCellera Biologics Competitors Phibro Animal Health Competitors Gyre Therapeutics Competitors Nuvation Bio Competitors Cronos Group Competitors Evolus Competitors Xeris Biopharma Competitors LENZ Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVGN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
